Benitec Biopharma Inc. (BNTC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Benitec Biopharma Inc. (BNTC) Healthcare & Pipeline Overview

Benitec Biopharma Inc. is a development-stage biotechnology company specializing in DNA-directed RNA interference therapeutics for chronic and life-threatening conditions. Their pipeline focuses on genetic medicines, including BB-301 for oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection, positioning them within the innovative gene therapy market.

What Is the Investment Thesis for BNTC?

Benitec Biopharma presents a high-risk, high-reward investment profile typical of development-stage biotech companies. The core value driver lies in the successful clinical development and eventual commercialization of BB-301 for OPMD and BB-103 for chronic HBV. Positive clinical trial data for either program could serve as a significant catalyst, driving substantial stock appreciation. However, the company's negative gross margin of -11.9% and a profit margin of -8327.9% underscore the financial challenges inherent in drug development, requiring careful monitoring of cash burn and potential future capital raises. The low Beta of 0.12 suggests the stock is less volatile than the overall market, but this may not fully capture the inherent risks of biotechnology investments.

Based on FMP financials and quantitative analysis

BNTC Key Highlights

Market capitalization of $420M, reflecting investor valuation of the company's pipeline and technology.

• Negative gross margin of -11.9%, indicative of the high costs associated with research and development in the biotechnology sector.
• Profit margin of -8327.9%, highlighting the company's current lack of revenue and significant investment in its drug development programs.
• Beta of 0.12, suggesting relatively low volatility compared to the broader market, but potentially masking the inherent risks of biotechnology investments.
• Focus on DNA-directed RNA interference (ddRNAi) technology, positioning the company in the innovative gene therapy space.

Who Are BNTC's Competitors?

BNTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BNTC's Key Strengths?

Proprietary DNA-directed RNA interference (ddRNAi) technology.

• Pipeline of genetic medicine candidates targeting unmet medical needs.
• Experienced management team with expertise in drug development.
• Focus on rare diseases, potentially leading to orphan drug designation.

What Are BNTC's Weaknesses?

Development-stage company with no approved products and no recurring revenue.

• High cash burn and reliance on equity financing.
• Significant regulatory and clinical trial risks.
• Small number of employees (16), potentially limiting operational capacity.

What Could Drive BNTC Stock Higher?

Clinical trial data releases for BB-301 in OPMD.

• Clinical trial data releases for BB-103 in chronic HBV infection.
• Potential strategic partnerships or collaborations.
• Advancements in the development of the ddRNAi platform.

What Are the Key Risks for BNTC?

Negative return on equity (-34.8%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory hurdles and rejection of drug candidates.
• Competition from other biotechnology companies.
• High cash burn and reliance on equity financing.
• Patent challenges or expiration of key patents.

What Are the Growth Opportunities for BNTC?

• BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD): OPMD is a rare genetic disorder with limited treatment options, representing a significant unmet medical need. If BB-301 demonstrates efficacy and safety in clinical trials, it could capture a substantial portion of this market. The OPMD market is estimated to grow as awareness and diagnostic capabilities improve, potentially reaching hundreds of millions of dollars. The timeline for commercialization depends on successful clinical trial outcomes, with potential for market entry within the next 3-5 years.
• BB-103 for Chronic Hepatitis B Virus (HBV) Infection: Chronic HBV infection affects millions of people worldwide, and current treatments are not always effective. BB-103 has the potential to offer a new therapeutic approach by targeting the viral RNA. The global market for HBV treatments is substantial, exceeding billions of dollars annually. Successful development and approval of BB-103 could provide Benitec with a significant revenue stream. Clinical trials are ongoing, with potential for market entry in 5-7 years if successful.
• Expansion of ddRNAi Platform: Benitec's DNA-directed RNA interference (ddRNAi) platform has the potential to be applied to a wide range of genetic diseases. The company could expand its pipeline by developing new ddRNAi-based therapeutics for other indications. This would diversify the company's risk and increase its long-term growth potential. The market for gene therapies is expected to continue to grow rapidly, providing opportunities for Benitec to leverage its platform.
• Strategic Partnerships and Collaborations: Benitec could pursue strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships could provide access to additional funding, expertise, and resources. The biotechnology industry is characterized by collaborations, and Benitec could benefit from leveraging external expertise.
• Orphan Drug Designation and Regulatory Advantages: BB-301 for OPMD may be eligible for orphan drug designation, which provides regulatory advantages such as market exclusivity and tax credits. These advantages can significantly enhance the commercial potential of the drug. Orphan drug designation is often granted for drugs targeting rare diseases, and Benitec could leverage this to its advantage.

What Are BNTC's Competitive Advantages?

• Proprietary DNA-directed RNA interference (ddRNAi) technology platform.
• Patent protection for its drug candidates and technology.
• Focus on rare diseases with limited treatment options, potentially leading to orphan drug designation.

What Does BNTC Do?

Benitec Biopharma Inc., founded in 1995 and headquartered in Hayward, California, is a development-stage biotechnology company dedicated to creating novel genetic medicines. The company focuses on utilizing DNA-directed RNA interference (ddRNAi) to develop therapies for chronic and life-threatening human conditions. ddRNAi is a gene-silencing technology that aims to reduce the expression of disease-causing genes. Benitec's primary focus is on advancing its pipeline of ddRNAi-based therapeutics. Their lead product candidate, BB-301, is an adeno-associated virus (AAV) based gene therapy agent designed to treat oculopharyngeal muscular dystrophy (OPMD), a rare genetic disorder causing progressive muscle weakness. Another key program is BB-103, which is being developed for the treatment of chronic hepatitis B virus (HBV) infection. As a development-stage company, Benitec Biopharma is currently focused on preclinical and clinical development, with no products yet approved for commercial sale. The company's strategy involves leveraging its ddRNAi platform to create innovative therapies for diseases with significant unmet medical needs.

What Products and Services Does BNTC Offer?

• Develops novel genetic medicines using DNA-directed RNA interference (ddRNAi).
• Focuses on therapies for chronic and life-threatening human conditions.
• Develops BB-301, an adeno-associated virus (AAV) based gene therapy for treating oculopharyngeal muscular dystrophy (OPMD).
• Develops BB-103 for the treatment of chronic hepatitis B virus (HBV) infection.
• Utilizes gene-silencing technology to reduce the expression of disease-causing genes.
• Conducts preclinical and clinical development of its drug candidates.

How Does BNTC Make Money?

• Focuses on research and development of genetic medicines.
• Generates revenue through potential future licensing agreements or commercialization of approved products.
• Funds operations through equity financing and potential future partnerships or grants.

What Industry Does BNTC Operate In?

Benitec Biopharma operates within the biotechnology industry, a sector characterized by high innovation, long development timelines, and significant regulatory hurdles. The market for gene therapies is rapidly expanding, driven by advancements in technology and a growing understanding of genetic diseases. Competition is intense, with numerous companies pursuing similar approaches. Benitec's focus on ddRNAi differentiates it from companies using other gene therapy modalities. The biotechnology industry is subject to stringent regulatory oversight by agencies such as the FDA, requiring extensive clinical trials to demonstrate safety and efficacy.

Who Are BNTC's Key Customers?

• Patients suffering from oculopharyngeal muscular dystrophy (OPMD).
• Patients suffering from chronic hepatitis B virus (HBV) infection.
• Potential future patients with other genetic diseases treatable with ddRNAi technology.

Benitec Biopharma Inc. (BNTC) Valuation Context

Valued at $420M, BNTC is classified as a small-cap stock. Analyst price targets span from $16.00 to $25.00, with a consensus of $20.50. At the current price of $12.22, that implies approximately 68% upside potential. Relative to its peer group, BNTC's quantitative score of 27/100 is below the peer average of 80/100.

BNTC Revenue & Earnings Trend

In Q3 FY2026, BNTC generated $0 in top-line revenue. The company recorded a net loss of $11.9M, with diluted EPS of $-0.24. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BNTC averaged $-0.29 in diluted EPS.

Company Profile

Benitec Biopharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hayward, US. The company is led by CEO Jerel A. Banks. BNTC has traded publicly since 2014.

Return on equity for Benitec Biopharma Inc. stands at -34.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 56.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.4%, the inverse of the P/E and a quick read on earnings relative to price.

Benitec Biopharma Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 94.61 places it in the safe zone, indicating low near-term bankruptcy risk.

Benitec Biopharma Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 9.3% below estimates on average.

Over the past six months, Benitec Biopharma Inc. insiders filed 2 SEC Form 4 transactions — 1 sales and 1 purchases. On net that is roughly 17K shares disposed (about $401K), a signal worth weighing alongside the fundamentals.

BNTC Financials

BNTC Latest News

BNTC Analyst Consensus

BNTC MoonshotScore

Latest Benitec Biopharma Inc. Analysis

What Investors Ask About Benitec Biopharma Inc. (BNTC) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources